Shares of Biogen Idec Inc. fell Monday after JP Morgan cut its rating on the stock, saying the multiple sclerosis drug Tysabri could continue facing challenges in 2009 while the company lacks any catalysts to drive new revenue.
Researchers combing the human gene map have found four more areas that affect the risk of Alzheimer's disease and believe the studies are starting to point to new and better treatments.
Shares in Irish drugmaker Elan dived more than 50 percent to their lowest level since 2005 on Friday as a second product setback in a week shattered confidence in its line-up of biotech medicines.
Biogen Idec and Elannotified regulators of two confirmed cases of a potentially deadly brain disease in multiple sclerosis (MS) patients being treated with Tysabri.
A new groundbreaking research that could potentially lead to cure Alzheimer's disease and on how Chesapeake's CEO hopes to move Americans away from "expensive imported oil" to natural gas. Following are today's top videos:
Baxter researchers unveiled positive mid-stage test results on an intravenous drug, Wednesday, which is already in late-stage development in a very small number of patients.
Inconclusive test results for a new Alzheimer's drug caused an unjustified sell-off in stocks for pharmaceutical companies Elan and Wyeth, said Elan CEO Kelly Martin.
Keenly awaited details on Elan and Wyeth's new Alzheimer's drug bapineuzumab show it raised the risk of a potentially serious side effect, especially in people with a genetic risk of the disease, the companies said on Tuesday.
Don't look now, but in the first week of the new year shares of Elan stock lost nearly three-quarters of its value last year on safety concerns about the multiple sclerosis drug Tysabri, which it shares with Biogen Idec, and efficacy concerns over the Alzheimer's drug it's developing with Wyeth... Read More